GlobeNewswire Inc | Mar 5, 2021 04:30PM EST

March 05, 2021

Montrouge, France, March 5, 2021

DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Conference

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tass, Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference being held March 9-10, 2021.

A webcast of the presentation at the H.C. Wainwright Healthcare Conference will be available on the Investors & Media section of the Companys website beginning Tuesday, March 9th at 7:00 a.m. ET: https://www.dbv-technologies.com/investor-relations/.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com



Attachment

-- PDF Version